Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib Extension Study in Hematologic Malignancies
NCT01090414Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2010
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idelalisib in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Started Mar 2010; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01090414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090414.